Navigation Links
Bortezomib in Medical News

ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity

ATLANTA, GA, December 8, 2007 -- Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma. Data from one study showed that 10 of 21 (48 percent) evalu...

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

... multiple myeloma patients previously treated with bortezomib (VELCADE((R))). The SPA provides agreement that t...d Safety of Perifosine Added to the Combination of bortezomib and Dexamethasone in Multiple Myeloma Patients Pre... safety of KRX-0401 vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, wil...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

... Phase I study of elotuzumab (HuLuc63) in combination with bortezomib in relapsed multiple myeloma Lead investigator: Andrzej Jakubo...30 pm ET Panobinostat & bortezomib phase I trial in multiple myeloma Lead investigator: Orhan Se...

Green tea may negate the effects of a common cancer therapy

...ract the anticancer effects of one cancer therapy, bortezomib (Velcade ), and may be contraindicated for pati...valuated whether the combination of green tea and bortezomib would improve outcomes against multiple myeloma, ...d to find that the EGCG compound seemed to prevent bortezomib from fighting the disease by blocking its proteas...

Green Tea May Negate the Effects of a Common Cancer Therapy

...ract the anticancer effects of one cancer therapy, bortezomib (Velcade(R)), and may be contraindicated for patie...evaluated whether the combination of green tea and bortezomib would improve outcomes against multiple myeloma, a...d to find that the EGCG compound seemed to prevent bortezomib from fighting the disease by blocking its proteaso...

Cancer drug effectively treats transplant rejections

...ge role in the humoral immune response by making immune proteins that attack transplanted organs. "We found a body of literature demonstrating that bortezomib works well in suppressing transplant rejection in the laboratory," says Woodle, lead author of the study and chief of transplant surgery at UC. "Moreo...

Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology

...2 Clinical Trial of Perifosine in combination with bortezomib (+/- dexamethasone) on Tuesday, December 9, 2008 a... of a Multicenter Trial of Perifosine (KRX-0401) + bortezomib in Patients with Relapsed or Relapsed / Refractory...btained to date on the combination of KRX-0401 and bortezomib in relapsed and refractory multiple myeloma patien...

VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients

...interactions between proteasome inhibitors such as bortezomib and histone deacetylase inhibitors such as vorinos...sess whether patients who have previously received bortezomib respond differently from those who have never been treated with bortezomib. bortezomib administered alone has recently been approved for ...

Combination Therapy Helps to Combat Myeloma

...at preclude them from receiving high doses of the standard drug therapies melphalan and prednisone, or a transplant, experts said. "The addition of bortezomib (Velcade) resulted in significant prolongation in time to disease progression with a reduction of 52 percent in risk of progression," said lead resear...

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

...A(1) trial showed 30% complete remission rate with bortezomib compared to 4% for the control arm. Importantly, patients treated with bortezomib also experienced a survival benefit," said Paul Ri...ur days every 6 weeks or the same MP schedule with bortezomib (1.3 mg/m2) IV on days 1, 4, 8, 11, 22, 25, 29 and...
Bortezomib in Medical Technology

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced updated clinical results from an ongoing Phase 1/2...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

- First of three ongoing randomized chemotherapy combination trials to evaluate HGS-ETR1 in the treatment of specific cancers - ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today reported initial topline results from an ongoing randomiz...

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

...57 induces an anti-inflammatory response at doses less than one tenth the Maximum Tolerated Dose (MTD). In contrast, nonselective inhibitors, such as bortezomib and carfilzomib, induce anti-inflammatory responses only at or near their MTD. These findings also underline the key role played by the immunoproteas...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

...tients enrolled in the Phase 2 trial have relapsed following treatment with bortezomib and an immunomodulatory agent, such as thalidomide or lenalidomide, and wer...ase 2 clinical trial designed to evaluate response rates based on patients' bortezomib treatment history demonstrated substantial response rates, particularly amo...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... Phase 1/2 study of perifosine in combination with bortezomib (+/- dexamethasone) in multiple myeloma patients relapsed from or refractory to bortezomib NEW YORK, Dec. 9 /PRNewswire-FirstCall/ -...ivity of perifosine (KRX-0401) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refr...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

...cer Centers-Parker: Results of a Phase II study of bortezomib in patients with relapsed or refractory indolent l...ncer Centers-Midtown: Phase II open label-trial of bortezomib in patients with multiple myeloma who have undergo... Centers-Midtown: Phase II trial of combination of bortezomib and Rituximab in relapsed and/or refractory Walden...

Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology

...6:00 p.m. -- 8:00 p.m. PST Session: Molecular Pharmacology, Drug Resistance Poster II -- Non-Proteasomal Targets of Proteasome Inhibitors bortezomib and Carfilzomib (Abstract #2657) Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding Therapy Poster II ...

Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone

.... Telik's proteasome inhibitors are orally active, non-peptide, non-boron based, and thus may lead to a drug candidate that might have advantages over bortezomib and other proteasome inhibitors. "The potentially favorable profile of these compounds was achieved through the use of our TRAP(R) computational dru...

Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma

...to evaluate patients' overall response rate after four cycles of carfilzomib. All patients enrolled in the trial have received prior treatment(s) with bortezomib and either lenalidomide or thalidomide and are refractory to their last treatment. A second open-label, multi-center Phase 2 trial of single-agent c...

Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...and helping patients fight cancer." Data from the following studies will be presented: -- The Effect of Pegylated Liposomal Doxorubicin Plus bortezomib in Multiple Myeloma Patients with Renal Insufficiency (Abstract 8562) Presentation: Saturday, May 31, 8:00 am - 12:00 pm CST, General ...

More>>

Bortezomib in Biological News

Massey researchers induce cell death in leukemia

...or of translational research, interactions between bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 from CuraGen Corporati...ed in human CLL cells isolated from five patients. bortezomib dramatically potentiated the lethality of both age...

An AIDS-related virus tricks cells to become tumors, new Penn study finds

...n be free to activate genes involved in growth of blood vessels to increase the blood supply to the tumor. "Use of such proteosome inhibitors as bortezomib as cancer therapeutic agents has been ongoing for the last four to five years and this study provides crucial step in understanding the mechanism for ...

Compound from marine bacteria shows potential as multiple myeloma therapy

...teasome inhibition is a key therapeutic target and bortezomib (Velcade tm) was the first in a new class of comp... Though less toxic than conventional chemotherapy, bortezomib does have significant side effects in some myeloma...e resistant to bortezomib. Because NPI-0052 and bortezomib attack the same intracellular target in different ...
Bortezomib in Biological Technology

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

... multiple myeloma patients previously treated with bortezomib (VELCADE(R)). The SPA provides agreement that the ...d Safety of Perifosine Added to the Combination of bortezomib and Dexamethasone in Multiple Myeloma Patients Pre...afety of perifosine vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, will...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

...l cancer and in combination with capecitabine for advanced metastatic colon cancer (placebo-controlled), as well as for perifosine in combination with bortezomib +/- dexamethasone in relapsed and refractory myeloma. About AEterna Zentaris Inc. AEterna Zentaris Inc. is a global biopharmaceutical compan...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

...al trial to date, of which 45 percent had no prior bortezomib experience and 55 percent relapsed following bortezomib treatment. In both arms, substantial response rat...s not been reached. Among patients with prior bortezomib exposure, 18 percent achieved partial responses an...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...tation and posters: Relationship of rapid M protein reduction to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma (MM) (Abstract 8591) General Poster Session, Saturday May 30, 8:00 am to 12:00 pm, Level...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

...trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. In addition, results from a Phase Ib/II study of carfilzomib in p...

Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology

...Activity in Relapsed Patients by Prior Exposure to bortezomib A second presentation by Dr. Vij described...gned to evaluate response rates based on patients' bortezomib treatment history. Patients enrolled in this tria...: Non-Proteasomal Targets of Proteasome Inhibitors bortezomib and Carfilzomib (Abstract #2657) and The Selective...

Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technology

...lecules for the enzymatic removal of ubiquitin markers in incorrectly folded proteins. The inventions also protect the use of the proteasome inhibitor bortezomib (Velcade (R)) for second medical use in cystic fibrosis (Velcade (R) has already been approved for use in humans to treat other indications). For ...

Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference

...echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas...

Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference

...echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas...

Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook

...echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas...
Bortezomib in Biological Dictionary

Proteasome

...easome , COP9 signalosome and related complexes) ... Proteasome , COP9 signalosome, TPPII ... Proteasome inhibitor drug for treating cancer. ... bortezomib is a highly selective, reversible inhibitor of the 26S proteasome . ... The Proteasome -Glo™ Cell-Based Assays(a,b) are homogeneous, luminescent ...
Other Tags
(Date:4/18/2014)... -- A group of scientists from the University ... Center on Aging has found interesting new information ... in Parkinson,s disease (PD). , Published in ... which assessed cognitive function in depressed and non-depressed ... therapy commonly used to treat motor symptoms of ...
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
(Date:4/20/2014)... lung, breast and pancreatic cancers also promote drug-resistance and ... California, San Diego School of Medicine have discovered a ... drug-resistant tumors that appears responsible for inducing tumor metastasis ... , The findings, published in the April 20, ... may point to new therapeutic opportunities for reversing drug ...
(Date:4/18/2014)... contraceptive pills in Peru found that 28 percent ... quality or falsified. Many pills released the active ... ingredient. One batch had no active ingredient at ... researchers at the Georgia Institute of Technology developed ... assess suspected counterfeit drugs and then characterize their ...
(Date:4/18/2014)... NC Ancient DNA adds a twist to the story ... to be published April 21 in the journal Proceedings ... from the bones of chickens that lived 200-2300 years ago ... ago domestic chickens may have looked far different from the ... of the traits we associate with modern domestic chickens -- ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2
Other Contents